Robert LeBoyer
Stock Analyst at Noble Capital Markets
(0)
# 3272
Out of 5,218 analysts
18
Total ratings
35.71%
Success rate
4.10%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Geovax Labs | Maintains: Outperform | 6 10 | 2.35 | 325.53% | 2 | Aug 19, 2024 | |
Unicycive Therapeuti... | Initiates Coverage On: Outperform | 6 | 0.71 | 745.07% | 1 | Feb 14, 2024 | |
Cadrenal Therapeutic... | Initiates Coverage On: Outperform | 60 | 11.2 | 435.71% | 1 | Dec 18, 2023 | |
Eledon Pharma | Initiates Coverage On: Outperform | 10 | 4.4 | 127.27% | 1 | Sep 27, 2023 | |
MAIA Biotechnology | Initiates Coverage On: Outperform | 14 | 1.98 | 607.07% | 1 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Sep 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 3840 | 0.24 | 1599900% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 150 | n/a | n/a | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 8 | 0.5 | 1500% | 2 | Aug 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 120 | 1.25 | 9500% | 1 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 8.41 | 42.69% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16500 | 0.1 | 16499900% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 15 | 4.47 | 235.57% | 2 | Mar 8, 2018 |